Loading...
XKRX
065660
Market cap245mUSD
Dec 05, Last price  
37,100.00KRW
1D
2.49%
1Q
51.43%
Jan 2017
56.54%
IPO
-4.13%
Name

Anterogen Co Ltd

Chart & Performance

D1W1MN
XKRX:065660 chart
P/E
P/S
52.08
EPS
Div Yield, %
Shrs. gr., 5y
2.38%
Rev. gr., 5y
10.82%
Revenues
6.93b
+6.66%
1,834,279,9603,532,247,7704,896,068,2605,357,319,2403,607,167,1704,147,568,0204,151,233,4708,121,552,7006,591,010,7906,500,249,5306,932,865,000
Net income
-2.29b
L-19.29%
-1,415,653,390-58,309,090371,659,590446,737,570-961,759,730-4,049,844,880-4,375,063,260-553,984,070-6,837,097,540-2,840,849,743-2,292,835,000
CFO
-860m
L-56.73%
-1,010,252,750844,493,920-130,648,830379,205,990-1,504,760,530-1,648,844,500-4,414,918,170-3,045,351,650-1,975,372,510-1,988,220,126-860,376,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
IPO date
Feb 15, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT